NewsLocation
Home / News
- October 27,2025Pharmosa Biopharm’s Systemic Sclerosis Drug Shows Breakthrough Phase I Results
- October 16,2025PharmaEssentia Sees Ropeg Market Doubling After New Clinical Data Release
- October 9,2025SunHawk Vision Biomed Submits FDA Phase III Application For Dry-Eye Ophthalmic Drug, With Clinical Enrollment Expected In 2026
- September 18,2025Caliway Pharma Presents CBL-514 Combination Therapy With Weight-Loss Injection At The European Diabetes Congress
- September 10,2025Caliway Biopharma’s CBL-514 Shows 8× Stronger Weight-Loss Effect In Animal Studies
- September 2,2025Imperative Care Announces FDA Clearance of Symphony Thrombectomy System, the First Large-Bore Continuous Vacuum System for Treatment of Pulmonary Embolism
- August 20,2025Polaris Group’s New Drug For Malignant Pleural Mesothelioma Under FDA Review; U.S. Licensing To Accelerate Commercialization
- February 18,2025Acepodia’s ACE2016 Received TFDA Approval For Clinical Trials In Taiwan
- January 15,2025Mainstay Medical Announces Positive Outcomes from Landmark RESTORE Clinical Trial of ReActiv8®
- January 7,2025La Kaffa Group Targets 20% Revenue Growth In 2025; Acquires Hanlin Tea Room For NT$272M To Diversify Current F&B Portfolio
Contact
Taipei Office - IIH Assets Management Company Limited
- 7F, No.222, Sec.1, Fuhsing South Road Taipei, Taiwan 106
- Tel ： +886-2-27781658 | Fax ： +886-2-27781623
- Mail ： lingchen@integral-group.com
